Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05190471 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Bio-Path Holdings.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
4
Study locations

NCT05190471: Recruiting Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by Bio-Path Holdings.

NCT05190471 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is actively recruiting participants, run by Bio-Path Holdings. The registered enrollment target is 48 participants, below the 57-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (16% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05190471, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is actively recruiting participants, sponsored by Bio-Path Holdings.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
4
Study locations

Study Summary

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

Primary Outcome

Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria

Conditions Studied

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Interventions

  • DRUG BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
  • DRUG Decitabine (in combination with BP1002)

Study Locations (4)

California

  • Scripps Green Hospital - La Jolla
  • UCLA Medical Center - Los Angeles

New York

  • Weill Cornell Medical College - NewYork-Presbyterian Hospital - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2022-08-16
Est. Completion 2027-09
Phase Phase 1
Bio-Path Holdings

5 total trials

What NCT05190471 shows while recruiting

NCT05190471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 57-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (16% lower).

The record links to 2 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 2 interventions - of which BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide is the first listed.

NCT05190471 reports a single indexed study location in California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT05190471 about?

NCT05190471 is a clinical study titled "A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)". This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemi...

What is the current status of trial NCT05190471?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-08-16. Estimated completion is 2027-09.

What conditions does trial NCT05190471 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory.

What interventions are being tested in trial NCT05190471?

The interventions under investigation include: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide (DRUG), Decitabine (in combination with BP1002) (DRUG).

Who is sponsoring clinical trial NCT05190471?

This trial is sponsored by Bio-Path Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05190471 being conducted?

This trial has 4 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia, in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05190471's enrollment target sits among peer trials

48 5th of 16 higher than 12 of 16 other Acute Myeloid Leukemia, in Relapse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia, in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05190471

Source: ClinicalTrials.gov NCT05190471, the US trial registry maintained by the National Library of Medicine. NCT05190471 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.